Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by M&T Bank Corp

M&T Bank Corp reduced its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,216 shares of the biopharmaceutical company’s stock after selling 1,039 shares during the quarter. M&T Bank Corp’s holdings in Regeneron Pharmaceuticals were worth $3,479,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of REGN. Raymond James Financial Services Advisors Inc. grew its position in Regeneron Pharmaceuticals by 89.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,676 shares of the biopharmaceutical company’s stock worth $10,400,000 after buying an additional 7,891 shares during the period. San Francisco Sentry Investment Group CA grew its position in shares of Regeneron Pharmaceuticals by 460.0% in the second quarter. San Francisco Sentry Investment Group CA now owns 56 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 46 shares during the last quarter. Kistler Tiffany Companies LLC grew its position in shares of Regeneron Pharmaceuticals by 51.3% in the second quarter. Kistler Tiffany Companies LLC now owns 59 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 20 shares during the last quarter. Symmetry Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $715,000. Finally, Valeo Financial Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 5.2% in the second quarter. Valeo Financial Advisors LLC now owns 447 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 22 shares during the last quarter. Institutional investors own 85.89% of the company’s stock.

REGN has been the topic of several research reports. Citigroup increased their price target on shares of Regeneron Pharmaceuticals from $585.00 to $635.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, October 1st. ValuEngine lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 11th. Credit Suisse Group decreased their target price on shares of Regeneron Pharmaceuticals from $745.00 to $737.00 and set an “outperform” rating on the stock in a research report on Friday, November 6th. Finally, Barclays raised their target price on shares of Regeneron Pharmaceuticals from $615.00 to $675.00 in a research report on Thursday, August 6th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $628.52.

Shares of REGN stock opened at $559.29 on Tuesday. The company’s fifty day simple moving average is $577.13 and its 200-day simple moving average is $592.38. The company has a market cap of $59.50 billion, a PE ratio of 21.65, a P/E/G ratio of 1.80 and a beta of 0.51. Regeneron Pharmaceuticals, Inc. has a 52 week low of $328.13 and a 52 week high of $664.64. The company has a current ratio of 2.12, a quick ratio of 1.68 and a debt-to-equity ratio of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported $8.36 earnings per share for the quarter, missing the Zacks’ consensus estimate of $9.52 by ($1.16). The firm had revenue of $2.29 billion for the quarter, compared to analyst estimates of $2.09 billion. Regeneron Pharmaceuticals had a net margin of 37.30% and a return on equity of 26.71%. Regeneron Pharmaceuticals’s revenue for the quarter was up 31.6% on a year-over-year basis. During the same period in the previous year, the business posted $6.67 earnings per share. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 28.16 EPS for the current fiscal year.

In related news, EVP Plew Daniel P. Van sold 27,109 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $610.89, for a total transaction of $16,560,617.01. Following the completion of the sale, the executive vice president now directly owns 36,854 shares of the company’s stock, valued at approximately $22,513,740.06. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Marion Mccourt sold 1,000 shares of the firm’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $600.00, for a total transaction of $600,000.00. Following the sale, the senior vice president now directly owns 14,963 shares of the company’s stock, valued at $8,977,800. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 130,667 shares of company stock valued at $78,396,863. Company insiders own 11.84% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: How is a management fee different from a performance fee?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.